Hydroxyurea in the treatment of HIV-1

Annals of Pharmacotherapy

Volumn 34, Issue 1, 2000, Pages 89-93

  Gibbs, Matthew A ^a,b   Sorensen, Suellyn J ^c  

^a BUTLER UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

AIDS; HIV 1; Hydroxyurea

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ANEMIA; APHTHOUS ULCER; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG DOSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; HAIR LOSS; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUTROPENIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; XEROSTOMIA;

EID: 0033958540     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19004     Document Type: Article

References (24)

1. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-5.
2. Lori F, Gallo RC. Hydroxyurea and AIDS: an old drug finds new application? AIDS Res Hum Retroviruses 1995;11:1149-51.
3. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-7.
4. Back DJ, Kewn S, Hoggard PG, Henry-Mowatt JS, Barry MG. Enhanced activation of nucleoside analogues in the presence of hydroxyurea in-vitro (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
5. Lafeuillade A, Pellegrino P, Poggi C, Profizi N, Thiebaut C. Hydroxyurea and HIV-1 viremia. AIDS 1995;9:1290-1.
6. Giacca M, Zanussi S, Comar M, Simonelli C, Vaccher E, de Paoli P, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologic and clinical evaluation. J Infect Dis 1996;174:204-9.
7. Rossero R, McKinsey D, Green S, Andron L, Pollard R. Open label combination therapy with stavudine, didanosine, and hydroxyurea in nucleoside experienced HIV-1 infected patients (abstract). 5th Conference on Retrovirus and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
8. Federici ME, Lupo S, Cahn P, Cassetti I, Redro R, Ruiz-Palacios G, et al. Hydroxyurea in combination regimens for the treatment of antiretroviral naïve HIV-infected adults (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
9. DHHS and Henry J Kaiser Foundation. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at www.hivatis. org. Accessed May 5, 1999.
10. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor (letter). Lancet 1998;352:199-200.
11. Lori F, Jessen H, Clerici M, Lieberman J, Walker B, Siliciano RF, et al. Suppression of HIV replication and cell proliferation leads to minimal levels of proviral DNA and to immune recovery (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
12. Schrader S, Burkhardt B, Gathe JC. Rapid viral reduction with a regimen of nelfinavir, stavudine, didanosine, and hydroxyurea (abstract). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24-27, 1998.
13. Zala C, Salomon H, Gun A, Rouleau D, Pampurro S, Perez H, et al. A pilot randomized comparative study of stavudine, didanosine, nevirapine with or without hydroxyurea in primary HIV infection (abstract). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1999.
14. Youle M, Mocroft A, Johnson M, Tyrer M, Madge S, Dykhoff A, et al. Surrogate marker responses to multidrug combinations comprising hydroxyurea, efavirenz, double protease inhibitors, and nucleoside analogues in protease inhibitor failures (abstract). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1999.
15. Young B, Burman W, Lichtenstein K. Initial responses of hydroxyurea in salvage antiretroviral therapy for patients with AIDS (abstract). Infectious Diseases Society of America 36th Annual Meeting, Denver, CO, November 12-15, 1998.
16. Graziani A, Gibson G, Fee R, Frank I. The activity of hydroxyurea-containing salvage regimens in highly experienced HIV-infected patients (abstract). Infectious Diseases Society of America 36th Annual Meeting, Denver, CO, November 12-15, 1998.
17. Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Long-term suppression of HIV-1 by hydroxyurea and didanosine (letter). JAMA 1997;277: 1437-8.
18. Montaner JS, Zala C, Conway B, Raboud J, Patenaude P, Rae S, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175: 801-6.
19. Frank I, Boucher H, Fiscus S, Flexner C, Valentine F, Gulick R, et al. Phase I/II dosing of once-daily hydroxyurea alone vs didanosine alone vs didanosine + hydroxyurea (abstract). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1999.
20. Rusnak J, Berry A, Stinnette B, Sharkey K, Zhov S, Dyall K, et al. DDI once daily vs twice daily alone and also with hydroxyurea once daily (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
21. Lori F. Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects. AIDS 1999;13:1433-42.
22. Package insert. Hydrea (hydroxyurea). Princeton, NJ: Bristol Laboratories, March 1998.
23. Bristol-Myers Squibb drug warning letter for Videx. Princeton, NJ: Bristol-Myers Squibb Immunology, November 19, 1999. www.bms.com/ immuno. Accessed December 1, 1999.
24. Package insert. Videx (didanosine). Princeton, NJ: Bristol-Myers Squibb, October 1999.